Duff & Phelps Investment Management Co. lowered its position in Icon Plc (NASDAQ:ICLR) by 0.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 145,559 shares of the medical research company’s stock after selling 93 shares during the period. Duff & Phelps Investment Management Co.’s holdings in Icon Plc were worth $14,234,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. UBS Asset Management Americas Inc. boosted its stake in shares of Icon Plc by 43.0% in the fourth quarter. UBS Asset Management Americas Inc. now owns 234,818 shares of the medical research company’s stock worth $17,659,000 after buying an additional 70,654 shares in the last quarter. GW&K Investment Management LLC boosted its stake in shares of Icon Plc by 16.8% in the first quarter. GW&K Investment Management LLC now owns 7,300 shares of the medical research company’s stock worth $582,000 after buying an additional 1,050 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Icon Plc by 741.0% in the first quarter. Bank of Montreal Can now owns 202,675 shares of the medical research company’s stock worth $16,156,000 after buying an additional 178,576 shares in the last quarter. Atria Investments LLC purchased a new stake in shares of Icon Plc during the first quarter worth about $214,000. Finally, Cim LLC boosted its stake in shares of Icon Plc by 4.6% in the first quarter. Cim LLC now owns 6,095 shares of the medical research company’s stock worth $486,000 after buying an additional 270 shares in the last quarter. 92.55% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Icon Plc (NASDAQ ICLR) opened at 101.40 on Friday. The firm’s 50-day moving average price is $100.50 and its 200 day moving average price is $89.05. The company has a market capitalization of $5.48 billion, a PE ratio of 20.57 and a beta of 0.60. Icon Plc has a 1-year low of $73.76 and a 1-year high of $109.32.
Icon Plc (NASDAQ:ICLR) last announced its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.01. Icon Plc had a net margin of 15.04% and a return on equity of 26.34%. The firm had revenue of $431 million during the quarter, compared to the consensus estimate of $430.68 million. During the same period last year, the firm earned $1.14 EPS. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Equities analysts predict that Icon Plc will post $5.32 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Icon Plc (ICLR) Stake Cut by Duff & Phelps Investment Management Co.” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://transcriptdaily.com/2017/08/13/icon-plc-iclr-stake-cut-by-duff-phelps-investment-management-co.html.
A number of equities research analysts have recently issued reports on ICLR shares. Zacks Investment Research cut Icon Plc from a “hold” rating to a “sell” rating in a report on Wednesday, April 26th. Evercore ISI boosted their price objective on Icon Plc from $91.50 to $92.00 and gave the stock an “outperform” rating in a report on Friday, April 28th. Jefferies Group LLC restated a “hold” rating on shares of Icon Plc in a report on Thursday, May 11th. ValuEngine cut Icon Plc from a “buy” rating to a “hold” rating in a report on Wednesday, May 31st. Finally, Credit Suisse Group restated an “outperform” rating and set a $102.00 price objective (up previously from $91.00) on shares of Icon Plc in a report on Tuesday, June 6th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $108.38.
About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.